Skip to main content
Clinical Trials/NCT01817218
NCT01817218
Completed
Phase 1

Feasibility and Safety and Evaluation of the Potential Efficacy of Autologous Platelet-rich Plasma in the Treatment of Vascular Venous Ulcers Compared to Moist Wound Care in a Primary Care Setting

Basque Health Service1 site in 1 country40 target enrollmentJune 2013

Overview

Phase
Phase 1
Intervention
Platelet Rich Plasma
Conditions
Chronic Ulcer
Sponsor
Basque Health Service
Enrollment
40
Locations
1
Primary Endpoint
REDUCTION IN ULCER SIZE
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

INTRODUCTION: Vascular ulcers are an important pathology in the daily medical practice in all the assistance levels, and they have big repercussion referring to individual, social and labour levels, supposing a big consumption of human and material resources.The cure with autologous platelet rich plasma (autologous PRP) has demonstrated in different studies a decrease in the cicatrization time comparing to conventional methods in hospital levels, which becomes interesting contrasting its efficacy in primary care.

AIM:Evaluate the practicability, security and potential of the autologous PRP in the treatment of vascular ulcers, comparing to the conventional treatment ( cure with humid environment), in primary care patients with chronic venous insufficiency in C-6 degree (CEAP classification).

DESIGN:A pilot study will be executed, which will consist in a randomized clinical test, multicentred, in parallel groups and opened. 40 patients suffering of venous vascular ulcers will be studied, who will be between the age of 40-80 years old, and who will be attached to five health centers. Variables for the identification, following, result and patient profile have been defined. Emphasize the variables of "ulcer area decreasing", "CIVIQ index", "% one cure per week" .

Registry
clinicaltrials.gov
Start Date
June 2013
End Date
April 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Basque Health Service
Responsible Party
Principal Investigator
Principal Investigator

Kepa M. San Sebastián Moreno

Dr.

Basque Health Service

Eligibility Criteria

Inclusion Criteria

  • Patients resident in Barakaldo, who are seen in treatment rooms at the Zaballa outpatient clinic or one of the following health centres: Zaballa, La Paz, Urban, or San Vicente, in the Ezkerraldea-Enkarterri Health Region of the Basque Health Service - Osakidetza.
  • Men or women of 40 to100 years of age
  • Patients with stage C6 chronic venous insufficiency according to the CEAP classification
  • Patients with vascular ulcers which have not responded to conventional treatment in 2 to 6 months
  • Patients who present an analytical before entering the study with a normal range of number of platelets, red blood cells and hematocrit
  • An ulcer of 3-5 cm in diameter
  • An ABI of greater than or equal to 0.8 or less than or equal to 1.
  • Independent patients or with sufficient family support
  • Patients have given written informed consent

Exclusion Criteria

  • Patients with chronic treatment with immunosuppressive or retroviral drugs
  • Coagulopathies
  • Patients with chronic infectious diseases
  • Patients under radiotherapy or chemotherapy
  • Patients with a history of neoplasia
  • Patients with more than two active ulcers
  • Pregnant women
  • Patients with active cellulitis or fever
  • An ABI of less than 0.8 or more than 1.5.

Arms & Interventions

PRP (Platelet Rich Plasma)

PRP treatment of vascular ulcers one a week PRP: a volume of 9-30 ml of blood will be collected from the patient (depending of the size of their ulcer) in sterile 4.5-ml tubes containing 3.8% sodium citrate, which will bind to the calcium ions, preventing clot formation we will add 50 μl of CaCl2 per ml liquid plasma. The extraction of the PRP fraction by sticking with a syringe and the adding of CaCl2 should be performed under sterile conditions.

Intervention: Platelet Rich Plasma

Osakidetza protocol

Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in "Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza", 2011). The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice.

Intervention: Osakidetza protocol

Outcomes

Primary Outcomes

REDUCTION IN ULCER SIZE

Time Frame: Change from baseline at 9 weeks

Difference in the area of the wound between week 9 and the first treatment session.

Change of ULCER AREA

Time Frame: Change from baseline at 9 weeks

Change from baseline at 9 weeks of the surface area of the ulcer, in cm3, measured using ImageJ software from the weekly the photographs of the wound

Change of the percentage OF PATIENTS WITH A ONLY ONE TREATMENT FOR WEEK

Time Frame: Change from baseline at 9 weeks

Change of the percentage OF PATIENTS WITH A ONLY ONE TREATMENT FOR WEEK

Change of the CIVIQ SCORE

Time Frame: Change from baseline to 9th week

change of the scale assessing quality of life of patients with chronic venous insufficiency, considering four dimensions (physical, psychological, social and pain) with a score ranging from 20 to 100, where 20 corresponds to the poorest quality of life and 100 to the best.

Study Sites (1)

Loading locations...

Similar Trials